We analyzed 160 young Waldenström Macroglobulinemia (WM) patients with a median age of 49 years (range 23-55 years), diagnosed between January 2000 and January 2019 in 14 Italian centers. At diagnosis, 70% of patients were asymptomatic. With a median follow-up of 5.6 years, 57% have been treated. As initial therapy 79% of patients received chemo-immunotherapy, 13% a chemo-free induction and 8% chemotherapy only. At relapse or progression, 6% underwent an autologous stem cell transplantation. Overall, 19% of patients received ibrutinib during the course of the disease. According to IPSSWM, 63% were classified as low risk, 27% as intermediate risk and 10% as high risk. Five-year OS was shorter in high-risk as compared with low or intermediate risk patients (92.9% vs 100% P =.002). According to revised IPSSWM, 92% were classified as very low or low risk and 8% as intermediate risk, with a shorter 5-year OS in the latter group (87.5% vs 100%, P =.028). The OS of young WM patients was not significantly reduced as compared with age-matched, sex-matched and calendar year-matched general population. Early diagnosis, absence of high-risk features in symptomatic patients and high efficacy of modern treatments are the main determinants of the excellent outcome of young WM patients.

Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies / Varettoni, M.; Ferrari, A.; Frustaci, A. M.; Ferretti, V. V.; Rizzi, R.; Motta, M.; Piazza, F.; Merli, M.; Benevolo, G.; Visco, C.; Laurenti, L.; Ferrero, S.; Gentile, M.; Del Fabro, V.; Abbadessa, A.; Klersy, C.; Musto, P.; Fabbri, N.; Deodato, M.; Dogliotti, I.; Greco, C.; Corbingi, A.; Luminari, S.; Arcaini, L.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 95:12(2020), pp. 1473-1478. [10.1002/ajh.25961]

Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

Luminari S.;
2020

Abstract

We analyzed 160 young Waldenström Macroglobulinemia (WM) patients with a median age of 49 years (range 23-55 years), diagnosed between January 2000 and January 2019 in 14 Italian centers. At diagnosis, 70% of patients were asymptomatic. With a median follow-up of 5.6 years, 57% have been treated. As initial therapy 79% of patients received chemo-immunotherapy, 13% a chemo-free induction and 8% chemotherapy only. At relapse or progression, 6% underwent an autologous stem cell transplantation. Overall, 19% of patients received ibrutinib during the course of the disease. According to IPSSWM, 63% were classified as low risk, 27% as intermediate risk and 10% as high risk. Five-year OS was shorter in high-risk as compared with low or intermediate risk patients (92.9% vs 100% P =.002). According to revised IPSSWM, 92% were classified as very low or low risk and 8% as intermediate risk, with a shorter 5-year OS in the latter group (87.5% vs 100%, P =.028). The OS of young WM patients was not significantly reduced as compared with age-matched, sex-matched and calendar year-matched general population. Early diagnosis, absence of high-risk features in symptomatic patients and high efficacy of modern treatments are the main determinants of the excellent outcome of young WM patients.
2020
95
12
1473
1478
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies / Varettoni, M.; Ferrari, A.; Frustaci, A. M.; Ferretti, V. V.; Rizzi, R.; Motta, M.; Piazza, F.; Merli, M.; Benevolo, G.; Visco, C.; Laurenti, L.; Ferrero, S.; Gentile, M.; Del Fabro, V.; Abbadessa, A.; Klersy, C.; Musto, P.; Fabbri, N.; Deodato, M.; Dogliotti, I.; Greco, C.; Corbingi, A.; Luminari, S.; Arcaini, L.. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 95:12(2020), pp. 1473-1478. [10.1002/ajh.25961]
Varettoni, M.; Ferrari, A.; Frustaci, A. M.; Ferretti, V. V.; Rizzi, R.; Motta, M.; Piazza, F.; Merli, M.; Benevolo, G.; Visco, C.; Laurenti, L.; Ferrero, S.; Gentile, M.; Del Fabro, V.; Abbadessa, A.; Klersy, C.; Musto, P.; Fabbri, N.; Deodato, M.; Dogliotti, I.; Greco, C.; Corbingi, A.; Luminari, S.; Arcaini, L.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1249566
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact